Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Study acronym: CHESS
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Aug 2026 → Dec 2026
See other at-risk trials from ETOP IBCSG Partners Foundation

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 2026 to Dec 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 5 of 8 entries
    • Study description revised
    • Site details revised at 1 of 14 sites
    • Publications: details revised at 10 of 10 entries
  2. Study sites: 15 to 14v29
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
    v28
  4. Site details revised at 10 of 15 sitesv27
  5. Site details revised at 1 of 15 sitesv26
Show 24 earlier versionsHide 24 earlier versions
  1. Study sites: 14 to 15v25
  2. Site details revised at 9 of 14 sitesv24
  3. Site details revised at 1 of 14 sitesv23
  4. Site details revised at 1 of 14 sitesv22
  5. Study sites: 13 to 14v21
  6. Site details revised at 1 of 13 sitesv20
  7. Site details revised at 1 of 13 sitesv19
  8. Site details revised at 1 of 13 sitesv18
  9. Site details revised at 2 of 13 sitesv17
  10. Site details revised at 1 of 13 sitesv16
  11. Site details revised at 10 of 13 sitesv15
  12. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 13 of 13 sites
    v14
  13. Study sites: 11 to 13v13
  14. Enrollment target: 48 to 96v12 Show 6 more changesShow less
    • Primary completion date: Sep 2022 to Aug 2026
    • Study completion date: Dec 2023 to Dec 2026
    • Interventions: Carboplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Radical radiotherapy - definitive local treatment. (Radiation), Stereotactic body… to Carboplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Radical radiotherapy - definitive local treatment. (Radiation), Stereotactic body…
    • Eligibility criteria expanded, about 60 words
    • Secondary endpoints: details revised at 5 of 8 entries
    • Study description expanded, about 84 words
  15. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 47 to confirmed 48
    • Site details revised at 11 of 11 sites
    v11
  16. Primary completion date: Dec 2021 to Sep 2022
    • Study completion date: Dec 2021 to Dec 2023
    v10
  17. Study sites: 10 to 11v9
  18. Site details revised at 1 of 10 sitesv8
  19. Site details revised at 1 of 10 sitesv7
  20. Site details revised at 1 of 10 sitesv6
  21. Study sites: 11 to 10v5
  22. Site details revised at 1 of 11 sitesv4
  23. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2019 to Nov 19, 2019
    • Site details revised at 11 of 11 sites
    v3
  24. Start date: Aug 2019 to Oct 2019v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT03965468
Lead Sponsor ETOP IBCSG Partners Foundation
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Non-small Cell Lung Cancer, Stage IV, Oligometastasis
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov